Systemic lupus erythematosus: modern strategies for management - a moving target

被引：10
作者：
King, Jennifer K. [1 ]
Hahn, Bevra H. [2 ]
机构：
[1] Univ Calif Los Angeles, Div Rheumatol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Div Rheumatol, Los Angeles, CA USA
来源：
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2007年 / 21卷 / 06期
关键词：
biologics; cyclophosphamide; monoclonal antibodies; mycophenolate mofetil; systemic lupus erythematosus;
D O I：
10.1016/j.berh.2007.09.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rapid advances in understanding the immunopathogenesis of systemic lupus erythematosus (SLE) have yielded an unprecedented era of discovery of new targets with therapeutic potential. Recent clinical trials have also shed light on the optimal utility of several traditional therapies used in our SLE armamentarium.
引用
收藏
页码：971 / 987
页数：17
相关论文
共 104 条
[1]   LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus -: Results from a randomized, double-blind, placebo-controlled study [J].
Alarcón-Segovia, D ;
Tumlin, JA ;
Furie, RA ;
McKay, JD ;
Cardiel, MH ;
Strand, V ;
Bagin, RG ;
Linnik, MD ;
Hepburn, B .
ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :442-454
[2]  
ALERT F, 2006, RITUXIMAB INFORM
[3]  
[Anonymous], GENDER TECHNOLOGY DE
[4]   Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus -: An open-label study [J].
Aringer, M ;
Graninger, WB ;
Steiner, GN ;
Smolen, JS .
ARTHRITIS AND RHEUMATISM, 2004, 50 (10) :3161-3169
[5]   Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus [J].
Aringer, Martin ;
Steiner, Guenter ;
Graninger, Winfried B. ;
Hoefler, Elisabeth ;
Steiner, Carl W. ;
Smolen, Josef S. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (01) :274-279
[6]   THERAPY OF LUPUS NEPHRITIS - CONTROLLED TRIAL OF PREDNISONE AND CYTOTOXIC DRUGS [J].
AUSTIN, HA ;
KLIPPEL, JH ;
BALOW, JE ;
LERICHE, NGH ;
STEINBERG, AD ;
PLOTZ, PH ;
DECKER, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (10) :614-619
[7]   Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus [J].
Baechler, EC ;
Batliwalla, FM ;
Karypis, G ;
Gaffney, PM ;
Ortmann, WA ;
Espe, KJ ;
Shark, KB ;
Grande, WJ ;
Hughes, KM ;
Kapur, V ;
Gregersen, PK ;
Behrens, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) :2610-2615
[8]   SULINDAC-INDUCED ASEPTIC-MENINGITIS [J].
BALLAS, ZK ;
DONTA, ST .
ARCHIVES OF INTERNAL MEDICINE, 1982, 142 (01) :165-166
[9]   CLINICAL-FEATURES OF SYSTEMIC LUPUS-ERYTHEMATOSUS - DIFFERENCES RELATED TO RACE AND AGE OF ONSET [J].
BALLOU, SP ;
KHAN, MA ;
KUSHNER, I .
ARTHRITIS AND RHEUMATISM, 1982, 25 (01) :55-60
[10]   Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus [J].
Barile-Fabris, L ;
Ariza-Andraca, R ;
Olguín-Ortega, L ;
Jara, LJ ;
Fraga-Mouret, A ;
Miranda-Limón, JM ;
de la Mata, JF ;
Clark, P ;
Vargas, F ;
Alcocer-Varela, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (04) :620-625
12345678910